Lifecore Biomedical (LFCR) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lifecore Biomedical (LFCR) has outperformed Upstream Bio (UPB) over the past year, losing 4.5% versus a loss of 75.3%. Upstream Bio is the larger company by market cap ($252.5 million vs $244.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LFCR | UPB |
|---|---|---|
| Share price | $6.44 | $4.61 |
| Market cap | $244.11M | $252.49M |
| 1-day change | -0.16% | +0.44% |
| YTD return | -21.27% | -83.02% |
| 1-year return | -4.45% | -75.31% |
| 5-year return | -34.35% | — |
| EPS (TTM) | $-1.27 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.98 | $33.68 |
| 52-week low | $3.63 | $4.50 |
| Distance from 52-week high | -28.29% | -86.31% |
| Analyst consensus | hold | none |
| Avg. price target upside | -2.48% | +575.49% |
| Average volume | 264.01K | 605.35K |
| Shares outstanding | 37.91M | 54.77M |
| Employees | 382 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LFCR has outperformed UPB by 70.9 percentage points over the past year.
About Lifecore Biomedical
LFCR stock →Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities.
Health Care · Biotechnology: Pharmaceutical Preparations · 382 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
LFCR vs UPB FAQ
Which is bigger, Lifecore Biomedical or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $252.49M compared with $244.11M for Lifecore Biomedical (LFCR).
Which stock has performed better over the past year, LFCR or UPB?
LFCR returned -4.45% over the past 12 months, compared with -75.31% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Lifecore Biomedical and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.